Last updated: 2026-10-19 18:21:00. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Delcath Systems Inc. (DCTH) operates in the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS sector and is listed on NASDAQ. The stock is currently priced at $14.42, with a market capitalization of $488.56M and a P/E ratio of 918.34. Over the past 52 weeks, its price has ranged from $8.12 to $17.42. This page covers its latest market performance, valuation, price trends and company information.
$488.56M | |
$14.16 | |
$801,248,000,000.00 | |
$2.25 | |
$14.08 | |
89.49K | |
473.45K | |
918.34 | |
$17.42 | |
$8.12 | |
-- | |
-- |
Delcath Systems Inc. (DCTH) is currently trading at $14.42 as of 2026-10-19 18:19:00, up 2.38% ($0.33) from the previous close of $14.08
During today's regular trading session, DCTH has traded between $2.25 and $801,248,000,000.00, with a trading volume of 89.49K shares. The current price is near the lower end of today's range.
Over the past seven days, Delcath Systems Inc. (DCTH) moved from $15.04 to $14.42, representing a decline of 4.16% ($0.63).
The stock traded between $13.83 and $15.77 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 270.87 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 67.7%
DCTH is currently trading at $14.42, placing it 67.7% of the way from its 52-week low of $8.12 to its 52-week high of $17.42. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.
| Industry | SURGICAL & MEDICAL INSTRUMENTS & APPARATUS |
| Employees | 156 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Delcath Systems Inc. (DCTH) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.